United Therapeutics to Repurchase $477.6M in Shares, Completing $2B…

Event summary

United Therapeutics will repurchase $477.6M in shares via an accelerated share repurchase (ASR) agreement with Citibank.
This completes the company's $2B share repurchase authorization, with $1.5B already repurchased in March 2026 and an additional $22.4M in open-market transactions.
The ASR agreement is expected to settle in Q4 2026, with the final number of shares based on the average daily volume-weighted average price.
As of September 4, 2026, United Therapeutics had approximately 42.9 million shares outstanding.

The big picture

United Therapeutics' decision to complete its $2B share repurchase authorization underscores its confidence in future growth drivers and the belief that its current stock valuation does not reflect its full potential. This move aligns with broader trends in the biotech sector, where companies with strong cash positions are increasingly returning value to shareholders through share buybacks. The strategic anomaly here is the scale of the repurchase relative to the company's market cap, signaling a significant bet on its own future prospects.

What we're watching

Growth Drivers: How United Therapeutics' multiple growth drivers will impact its stock valuation and shareholder returns.
Market Valuation: Whether the market will reflect the company's growth potential as it approaches key inflection points.
Capital Allocation: The pace at which United Therapeutics will continue to return value to shareholders through share repurchases.